Anticancer effects of an oncolytic parvovirus combined with non-conventional therapeutics on pancreatic carcinoma cell lines

Acta Virologica

Volumn 53, Issue 1, 2009, Pages 57-60

  Raykov, Z ^a   Georgieva, P B ^a   Angelova, A ^a,b   Galabov, A S ^b   Rommelaere, J ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b INSTITUTE OF MICROBIOLOGY   (Bulgaria)

Author keywords

Norfloxacin; Pancreatic cancer; Parvovirus; Resveratrol

Indexed keywords

NORFLOXACIN; ONCOLYTIC PARVOVIRUS; RESVERATROL; ANTINEOPLASTIC AGENT; ONCOLYTIC VIRUS; STILBENE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; ONCOLYTIC VIROTHERAPY; PANCREAS CARCINOMA; TREATMENT OUTCOME; DRUG INTERACTION; GROWTH, DEVELOPMENT AND AGING; H-1 PARVOVIRUS; TUMOR CELL LINE;

H-1 PARVOVIRUS; PARVOVIRUS;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG INTERACTIONS; H-1 PARVOVIRUS; HUMANS; NORFLOXACIN; ONCOLYTIC VIRUSES; STILBENES;

EID: 65549103372     PISSN: 0001723X     EISSN: None     Source Type: Journal    
DOI: 10.4149/av_2009_01_57     Document Type: Article

References (11)

1. Angelova A, Galabov AS, Rommelaere J, Raykov Z (2007): Antitumour effects of combined radio- and parvovirotherapy in N-Ras-positive tumour cells. COM PTES RENDUS DE L ACADEMI E BULGAR E DES SCIENCES 60, 879-882.
2. Boya P, Andreau K, Poncet D, Zamzami N, Perfettini JL, Metivier D, Ojcius DM, Jäättelä M, Kroemer G (2003): Lysosomal membrane permeabilization induces cell death in a mitochondrion-dependent fashion. J. Exp. Med. 197, 1323-1334. doi:10.1084/jem.20021952 PMid:12756268 PMCid:2193790
3. Ding XZ, Adrian TE (2002): Resveratrol inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Pancreas 25, 71-76. doi:10.1097/00006676-200211000-00024 PMid:12409844
4. Di Piazza M, Mader C, Geletneky K, Herrero Y Calle M, Weber E, Schlehofer J, Deleu L, Rommelaere J (2007): Cytosolic activation of cathepsins mediates parvovirus H-1-induced killing of cisplatin and TRAI L-resistant glioma cells. J. Virol. 81, 4186-4198. doi:10.1128/JVI.02601-06 PMid:17287256 PMCid:1866092
5. Geletneky K, Herrero Y Calle M, Rommelaere J, Schlehofer JR (2005): Oncolytic potential of rodent parvoviruses for cancer therapy in humans: a brief review. J. Vet. Med. B. Infect. Dis. Vet. Public Health 52, 327-330. doi:10.1111/j.1439-0450.2005.00877.x PMid:16316394
6. Gocheva V, Zeng W, Ke D, Klimstra D, Reinheckel T, Peters C, Hanahan D, Joyce JA (2006): Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev. 20, 543-556. doi:10.1101/gad.1407406 (Pubitemid 43345321)
7. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008): Cancer statistics. CA Cancer J. Clin. 58, 71-96. doi:10.3322/CA.2007.0010 PMid:18287387
8. Mouria M, Gukovskaya AS, Jung Y, Buechler P, Hines OJ, Reber HA , Pandol SJ (2002): Food-derived polyphenols inhibit pancreatic cancer growth through mitochondrial cytochrome C release and apoptosis. Int. J. Cancer 98, 761-769. doi:10.1002/ijc.10202 (Pubitemid 34225629)
9. Raykov Z, Balboni G, Aprahamian M, Rommelaere J (2004): Carrier cell-mediated delivery of oncolytic parvoviruses for targeting metastases. Int. J. Cancer 109, 742-749. doi:10.1002/ijc.20013 (Pubitemid 38405623)
10. Raykov Z, Grekova S, Galabov AS, Balboni G, Koch U, Aprahamian M, Rommelaere J (2007): Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model. Oncol. Rep. 17, 1493-1499.
11. Vulfovich M, Rocha-Lima C (2008): Novel advances in pancreatic cancer treatment. Expert Rev. Anticancer. Ther. 8, 993-1002. doi:10.1586/14737140.8.6. 993 PMid:18533808